Garcia VC, Mansfield C, Leach C, Pierce A, Smith JC, Afonso M. Patient and caregiver preferences for hemophilia treatments: a discrete-choice experiment. Haemophilia. 2024 Mar;30(2):375-87. doi: 10.1111/hae.14928
Leung MW, Bazelier MT, Souverein PC, Uitdehaag BM, Klungel OH, Leufkens HG, Pajouheshnia R. Mapping the risk of infections in patients with multiple sclerosis: a multi-database study in the United Kingdom clinical practice research datalink GOLD and aurum. Mult Scler. 2022 Oct;28(11):1808-18. doi: 10.1177/13524585221094218.
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014 Jul;20(4):e296-303. doi: 10.1111/hae.12459
Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia. 2011 May 1;17(3):476-82.
Meads DM, Doward LC, McKenna SP, Fisk J, Twiss J, Eckert B. The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler. 2009 Oct 1;15(10):1228-38. doi: 10.1177/1352458509106714
Miret M, Perez-Gutthann S, Gutierrez LP, Viglietta V, Musch B, Greenberg S. Evaluation of the long-term safety of Cladribine tablets: design of a prospective 8-year safety registry. Poster presented at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS); 2009. Dusseldorf, Germany. [abstract] Mult Scler. 2009 Sep 8; 15(Issue Suppl_9):S239. doi: 10.1177/1352458509106963
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS). Mult Scler. 2009 Sep 1;15(9):1092-102.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.
Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.
Doward LC, McKenna SP, Meads DM, Twiss J, Hagell P, Oprandi N. Psychometric and scaling properties of the patient reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler. 2007 Jun;13(Suppl 2):S219.
Doward LC, Meads DM, Fisk JD, McKenna SP, Eckert BJ. Derivation of a unidimensional scale from the fatigue impact scale. Mult Scler. 2006 Sep;12(Suppl 1):S1-S228.